Response to Comments: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This policy article (A59844) summarizes comments received on Draft LCD DL39614 regarding molecular biomarker testing for risk stratification of cutaneous squamous cell carcinoma from several contractors. The article itself does not define or change coverage criteria; refer to the draft or final LCD for specific indications, limitations, documentation requirements, and frequency limits.

"This article is a summary of comments received from WOS, Palmetto GBS, CGS, and Noridian on Draft LCD 'Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma' (DL3..."

Sign up to see full coverage criteria, indications, and limitations.